An interventional study of Rhodiola rosea (low dose) and Rhodiola rosea (high dose) in Healthy Volunteers, sponsored by Jacksonville State University. Completed at 1 site in United States. Open to participants aged 18 Weeks to 40 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by Jacksonville State University · Not applicable, Interventional, and Basic science
This study will evaluate whether 7 days of Rhodiola rosea (golden root) supplementation can improve resistance-exercise performance and cognitive function in resistance-trained men and women. Participants will complete four 7-day periods in a randomized, double-blind, crossover order: (1) no-capsule control, (2) placebo, (3) low-dose Rhodiola rosea, and (4) high-dose Rhodiola rosea. On day 7 of each period, they will report to the laboratory for performance testing that includes bench press and leg press 1-repetition maximum (1RM), a third set to failure at 60% 1RM, Tendo-derived mean and peak power, a 30-second Wingate test, and the paper-and-pencil Stroop Color-Word Test for executive function. Secondary outcomes include ratings of perceived exertion, readiness to perform (visual analog scale), and heart rate and blood pressure measured at rest and 1 minute after exercise. The central hypothesis is that short-term Rhodiola rosea, compared with control and placebo, will produce small but measurable improvements in strength, set-to-failure volume, and Stroop performance, with minimal changes in hemodynamics.
Rationale: Rhodiola rosea is an adaptogenic plant extract that has shown modest, context-dependent effects on perception of effort, cognition, and exercise performance. Prior studies suggest that benefits may be more evident with acute or short-term administration; however, the results are heterogeneous. This study employs a within-subject approach in resistance-trained adults to minimize between-person variability and investigate potential dose-response effects over a short time frame.
Design overview: After screening and a familiarization visit, each participant completes four 7-day periods: (1) no-capsule control, (2) placebo, (3) low-dose RR, and (4) high-dose RR. Capsule periods are randomized and double-blind; the no-capsule control precedes capsule periods to avoid carryover of expectancy. Study staff, participants, and outcome assessors are blinded during capsule periods. On day 7 of each period, participants attend a single testing visit conducted under standardized conditions (time of day, pre-test instructions). Short-latency effects are targeted by scheduling capsule ingestion approximately 60 minutes before testing during capsule periods.
Intervention: Low- and high-dose RR are provided in identical-appearing capsules. Placebo capsules contain inert filler. Product identity, dose, and lot information are recorded in the Intervention section of the record. Capsule count and participant logs monitor adherence.
Standardization and compliance: Participants are asked to maintain their habitual training and diet and to refrain from using additional ergogenic aids for a period of 7 days. They record total energy and macronutrients for the three days before each testing day. Testing sessions follow a consistent order of tasks established during the familiarization phase. Resting vital signs are obtained after a seated rest; post-exercise measures are obtained 1 minute after completion of designated tasks.
Population: Resistance-trained adults (men and women) who meet eligibility criteria and provide informed consent. Additional eligibility details are specified in the Eligibility section of the record. The female hormonal status/menstrual phases are documented when available to aid in interpretation.
Data handling and analysis (overview): The primary analyses compare conditions within participants using linear mixed-effects models, with participant as a random effect and fixed terms for condition and period. Additional prespecified covariates (e.g., sex, pre-visit dietary intake) may also be included. Order and carryover are evaluated as appropriate. Missing data are handled using model-based methods consistent with the statistical plan.
Safety: Adverse events are monitored throughout each period, with procedures for reporting to the IRB per institutional policy.
Jacksonville State University is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants complete a 7-day control period during which no capsules are administered. On day 7 they report to the lab for testing (bench press and leg press 1RM, third set to failure at 60% 1RM, Tendo power, 30-s Wingate, and Stroop Color-Word Test), plus HR/BP and RPE. This arm is always completed first to establish baseline performance.
Participants ingest placebo capsules once daily for 7 days. On day 7, \~60 minutes after the final dose, they complete the same performance and cognitive testing battery (resistance exercises, Wingate, Stroop, HR/BP, RPE). This arm controls for expectancy and capsule intake.
Dietary Supplement: Placebo capsules
Participants ingest low-dose Rhodiola rosea (e.g., 200 mg/day) for 7 days. On day 7, \~60 minutes after dosing, they complete the laboratory testing session (bench/leg press 1RM and 60% to failure, Tendo power, 30-s Wingate, Stroop test, HR/BP, RPE) to determine whether short-term low-dose RR improves strength, muscular endurance, anaerobic performance, or executive function relative to control and placebo.
Dietary Supplement: Rhodiola rosea (low dose)
Participants ingest high-dose Rhodiola rosea (e.g., 1,500 mg/day) for 7 days. On day 7, \~60 minutes after dosing, they perform the identical performance and cognitive testing battery. This arm allows for comparison of a higher RR dose with low-dose, placebo, and control groups to assess dose-response effects on resistance performance and Stroop outcomes.
Dietary Supplement: Rhodiola rosea (high dose)
Participants will ingest a low-dose Rhodiola rosea extract (≈approximately 200 mg/day) once daily for 7 consecutive days. On day 7, \~60 minutes after the final dose, they will complete the exercise and cognitive testing battery (bench press, leg press, set to failure at 60% 1RM, Tendo power, 30-s Wingate, Stroop test, HR/BP, RPE). This intervention is used to determine whether short-term, lower-dose RR improves resistance performance and executive function compared with placebo and control.
Also known as: Rhodiola rosea extract 200 mg
Participants will ingest a high-dose Rhodiola rosea extract (≈approximately 1,500 mg/day) once daily for 7 consecutive days. On day 7, \~60 minutes after the final dose, they will complete the same performance and cognitive testing battery. This arm allows dose-response comparison with the low-dose RR, placebo, and no-capsule control conditions.
Participants will ingest matching placebo capsules once daily for 7 days. On day 7, \~60 minutes after capsule ingestion, they will complete the full testing battery. This intervention controls for expectancy, capsule handling, and timing.
Load volume (kg) during 3rd set to failure at 60% 1RM
Participants performed bench presses and leg presses at 60% of their familiarization 1RM. On the 3rd set, they lifted to volitional failure; load volume was calculated as load (kg) × repetitions. Values after administration of low- and high-dose Rhodiola rosea were compared with those of the placebo and control groups.
Time frame: Day 7 of each 7-day period
Wingate anaerobic test peak power
Participants completed a 30-s Wingate test on a cycle ergometer; peak power (W) was recorded. Values after low- and high-dose Rhodiola rosea were compared with those of the placebo and control to assess the effects on anaerobic performance.
Time frame: Day 7 of each 7-day period
Executive function (Stroop Color-Word Test)
The paper-and-pencil Stroop Color-Word Test is administered (Word, Color, and Color-Word, 45 s each). The total number of correct responses across the three sections is recorded. Higher scores indicate better executive control.
Time frame: Day 7 of each 7-day period
Readiness to Perform (Visual Analog Scale, 0-100 mm)
Participants rated six items before testing on a 0-100 mm line anchored 0 = strongly disagree (worse) and 100 = strongly agree (better): (1) I slept well last night; (2) I am looking forward to today's workout; (3) I am optimistic about my future performance; (4) I feel vigorous and energetic; (5) My appetite is great; (6) I have little muscle soreness. Scores were recorded in millimeters; higher values indicate better readiness (greater agreement).
Time frame: Day 7 of each 7-day period
Rating of Perceived Exertion (RPE) after resistance exercise
RPE is recorded 1 minute after the 3rd set of bench press and leg press using the Borg 6-20 scale. Higher values indicate greater perceived exertion.
Time frame: Day 7 of each 7-day period
Resting Heart Rate
Seated/resting heart rate measured before testing. Unit: beats per minute (bpm). Higher values indicate higher HR.
Time frame: Day 7 of each 7-day period
1-Minute Post-Exercise Heart Rate
Heart rate was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: beats per minute (bpm). Higher values indicate higher HR.
Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).
Resting Systolic Blood Pressure
Seated/resting SBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher SBP.
Time frame: Day 7 of each 7 days (pre-test).
Resting Diastolic Blood Pressure
Seated/resting DBP measured before testing using an automated oscillometric device per manufacturer guidelines. Unit: mmHg. Higher values indicate higher DBP.
Time frame: Day 7 of each 7 days (pre-test).
1-Minute Post-Exercise Systolic Blood Pressure
SBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher SBP.
Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).
1-Minute Post-Exercise Diastolic Blood Pressure
DBP was measured 60 s after completion of each exercise bout (bench press, leg press, Wingate). Unit: mmHg. Higher values indicate higher DBP.
Time frame: Day 7 of each 7 days (1-min post-bench press; 1-min post-leg press; 1-min post-Wingate).
Adverse Events / Side-Effects-Frequency (0-5 Likert)
Participants completed a side-effects questionnaire rating how often each symptom occurred using a 6-point scale (0 = none; 1 = minimal \[1-2/week\]; 2 = slight \[3-4/week\]; 3 = occasional \[5-6/week\]; 4 = frequent \[7-8/week\]; 5 = severe \[≥9/week\]). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more frequent). Each item was analyzed separately; an optional composite frequency score (item mean) was also recorded.
Time frame: Day 7 of each 7 days (post-condition).
Adverse Events / Side-Effects-Severity (0-5 Likert)
Description: Using the same questionnaire, participants rated how severe each symptom was on a 6-point scale (0 = none; 1 = minimal; 2 = slight; 3 = moderate; 4 = severe; 5 = very severe). Symptoms queried: dizziness, headache, fast/racing heart rate, heart skipping/palpitations, shortness of breath, nervousness, blurred vision, and "any other unusual/adverse effects." Scores range 0-5 per item; higher = worse (more severe). Each item was analyzed separately; an optional composite severity score (item mean) was also recorded.
Time frame: Day 7 of each 7 days (post-condition).
Plan to share: No — Individual participant data will not be shared because the dataset is small, includes performance and health-related variables that may permit re-identification of participants from a single institution, and consent did not explicitly cover public data sharing.
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jacksonville State University